Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co LtdfiledCriticalToyama Chemical Co Ltd
Priority to PT70050ApriorityCriticalpatent/PT70050A/en
Publication of PT70050ApublicationCriticalpatent/PT70050A/en
Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Antibacterial compsns. for medical applications contain (a) a cephalosporin of formula (I) or its salt: (where R1 is acetoxy, 1-methyl-1,2,3,4-tetrazol-5-ylthio or 5-methyl-1,3,4-thiadiazol-2-ylthio, and R2 is H or OH) and (b) a beta-lactamase inhibitor contg. a beta-lactam ring. Combinations of (a) and (b) have synergistically increased activity against resistant strains of Gram-negative bacteria, esp. E. coli, Proteus spp., K. pneumoniae and Ps. aeruginosa.
PT70050A1979-08-101979-08-10Process for preparing antibacterial compositions for medical use having synergistic effect
PT70050A
(en)
Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases